Drug Profile
Research programme: haemophilia gene therapy - Oxford BioMedica
Alternative Names: ReQuinateLatest Information Update: 27 Jan 2011
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class Gene therapies
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia A
Most Recent Events
- 15 Aug 2008 Gene-based therapeutic for the treatment of haemophillia A is available for licensing worldwide (http://www.oxfordbiomedica.co.uk)
- 28 Aug 2007 Preclinical development is ongoing
- 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Drug delivery systems pharmacodynamics section